12S149: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA (0775–0780)

Presenting Author(s)

• AK

  Alan Kivitz, MD

  Altoona Center for Clinical Research
  Duncansville, PA, United States

  Disclosure(s): AbbVie/Abbott: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Chemocentryx: Officer or Board Member (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Frescenius Kabi: Consultant (Ongoing); Genzyme: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Grunenthal: Consultant (Ongoing); Horizon: Consultant (Ongoing), Officer or Board Member (Ongoing); Janssen: Consultant (Ongoing), Officer or Board Member (Ongoing); Novartis: Officer or Board Member (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Selecta: Consultant (Ongoing); Takeda: Consultant (Ongoing); UCB: Officer or Board Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• SM

  Sina Mackay, MSc

  Fraunhofer-Institut für Intelligente Analyse- und Informationssysteme IAIS
  Sankt Augustin, Germany

  Disclosure information not submitted.
• AP

  Amy Peeters, BSc, MSc

  Sint maartenskliniek
  Nijmegen, Netherlands

  Disclosure information not submitted.
• 

  Cecile PHILIPPOTEAUX, MD, PharmD, MSc

  University Hospital Center of Lille
  Lille, France

  Disclosure information not submitted.
• LP

  Laura PINA VEGAS, MD, PhD

  Henri Mondor University Hospital (APHP), Rheumatology Department
  Créteil, France

  Disclosure information not submitted.
• MS

  Martin Stradner, MD

  Medical University of Graz
  Graz, Austria

  Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

• 2:00 PM - 2:10 PM PT

  Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
  

  Presenting Author: Amy Peeters, BSc, MSc – Sint maartenskliniek
• 2:10 PM - 2:15 PM PT

  Q&A
  
• 2:15 PM - 2:25 PM PT

  Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
  

  Presenting Author: Alan J. Kivitz, MD – Altoona Center for Clinical Research
• 2:25 PM - 2:30 PM PT

  Q&A
  
• 2:30 PM - 2:40 PM PT

  Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
  

  Presenting Author: Cecile PHILIPPOTEAUX, MD, PharmD, MSc – University Hospital Center of Lille
• 2:40 PM - 2:45 PM PT

  Q&A
  
• 2:45 PM - 2:55 PM PT

  The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis - A Randomized Controlled Trial
  

  Presenting Author: Martin Stradner, MD – Medical University of Graz
• 2:55 PM - 3:00 PM PT

  Q&A
  
• 3:00 PM - 3:10 PM PT

  Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
  

  Presenting Author: Laura PINA VEGAS, MD, PhD – Henri Mondor University Hospital (APHP), Rheumatology Department
• 3:10 PM - 3:15 PM PT

  Q&A
  
• 3:15 PM - 3:25 PM PT

  Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
  

  Presenting Author: Sina Mackay, MSc – Fraunhofer-Institut für Intelligente Analyse- und Informationssysteme IAIS
• 3:25 PM - 3:30 PM PT

  Q&A